Latest News

Tuesday, February 09, 2016 | Partnerships, Second Sight Medical Products

Second Sight Announces Exclusive Agreement with Tecnosalud to Bring the Argus II Retinal Prosthesis to Argentina

Second Sight Medical Products announced plans to expand into South America by signing an exclusive agreement with Tecnosalud to distribute the Argus II Retinal Prosthesis System in Argentina, accordin…

Read the full story

Tuesday, February 09, 2016 | Partnerships, STAAR Surgical

Staar Surgical and Memira Holding Announce Cooperation Agreement for Memira's Eye Clinics Throughout Scandinavia

Staar Surgical and Memira Holding, Sweden, announced they have entered into an agreement effective January 1, 2016, to provide STAAR's phakic intraocular lenses (ICL) as a primary and premium opti…

Read the full story

Tuesday, February 09, 2016 | Clinical Trials, SalutarisMD

SalutarisMD Clinical Results Presented at World Ophthalmology Congress

This week, Salutaris Medical Devices investigational therapy for wet AMD was featured at the World Ophthalmology Congress in two scientific poster presentations by Kamaljit Balaggan, MD.  Dr. Bal…

Read the full story

Tuesday, February 09, 2016 | Medical Studies

Mitochondrial Replacement 'Ethically Permissible,' IOM Says

A new consensus report issued by the Institute of Medicine finds that research into mitochondrial replacement techniques (MRTs), where an embryo has genetic information from three people, is "eth…

Read the full story

Monday, February 08, 2016 | Acquisitions/Mergers, Allergan

Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction

Pfizer announced the executive leadership team for the combined Pfizer and Allergan business following the close of the proposed transaction. As previously announced, following the closing, Brent Saun…

Read the full story

Monday, February 08, 2016 | Dry Eye

KPI Therapeutics Announces Expanded Drug Programs in Eye and Skin Diseases

KPI Therapeutics, a clinical-stage biotechnology company, announced it initiated two new research programs to treat such diseases as atopic dermatitis, dry eye syndrome, and uveitis at the BIO CEO &am…

Read the full story

Monday, February 08, 2016 | Product Releases, Glaukos Corporation

Glaukos Establishes Direct Sales Organization and Launches iStent inject Trabecular Micro-Bypass Stent in Australia

Glaukos Corporation announced that it has established a direct sales organization and launched the iStent inject Trabecular Micro-Bypass Stent in Australia, according to a company news release. The…

Read the full story

Friday, February 05, 2016 | Medical Studies

Using the Physics of Your Perfect Pancake to Help Save Sight

Understanding the textures and patterns of pancakes is helping UCL scientists improve surgical methods for treating glaucoma. The appearance of pancakes depends on how water escapes the batter mix dur…

Read the full story

Friday, February 05, 2016 | Medical Studies

Forecast: North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User

The North American ophthalmology cataract surgery devices market is estimated to witness a CAGR of 7.8% during the forecast period, 2014 to 2019, according to a report by Reportbuyer, a market researc…

Read the full story

Friday, February 05, 2016 | Medical Studies

High-Dose Statins May Ease Macular Degeneration for Some

High doses of cholesterol-lowering statin drugs - medicines such as Lipitor, Crestor and Zocor - may help people with macular degeneration, a small study suggests. In the early stage clinical trial,…

Read the full story

Friday, February 05, 2016 | Glaucoma

Glaucoma and Cataract Surgery: Two Roads Merging Into One

Recent years have demonstrated significant advances in the management of glaucoma through the use of novel microinvasive glaucoma devices. Furthermore, an increased understanding of the role of catara…

Read the full story

Thursday, February 04, 2016 | Dry Eye, Shire

FDA Acknowledges Receipt of Lifitegrast Resubmission; Begins 6-Month Review Period

Shire announced that the FDA has acknowledged receipt of the resubmission of the new drug application (NDA) for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire …

Read the full story

Thursday, February 04, 2016 | Cataract Surgery, FDA Approval/Clearance, Oculus

The Oculus Pentacam AXL with Optical Biometry Receives FDA Clearance

The new Oculus Pentacam AXL has received 510(k) clearance from the FDA. The device is capable of anterior segment tomography and optical biometry with a single measuring operation, according to a comp…

Read the full story

Thursday, February 04, 2016 | Medical Studies, American Academy of Ophthalmology, Sensimed

Smart Contact Lens Can Help Predict Glaucoma Progression in Patients

A contact lens with a built-in sensor could help determine which glaucoma patients have a higher risk of disease progression, according to a new study published online in the journal Ophthalmology. Re…

Read the full story

Thursday, February 04, 2016 | Partnerships, Bausch+Lomb, Prevent Blindness

Bausch + Lomb Partners with Prevent Blindness to Urge Americans to Fight for Their Sight

This month, Bausch + Lomb is partnering with Prevent Blindness to encourage the public to give vision the same attention as heart health during age-related macular degeneration (AMD) awareness month. …

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $13.80  0.00% 
 Akorn, Inc. $24.52  0.00% 
 Alimera Sciences, Inc. $2.11  0.00% 
 Allergan $272.34  0.00% 
 Avalanche Biotechnologies $4.15  0.00% 
 Bayer $105.90  0.00% 
 Can-Fite Biopharma $2.00  0.00% 
 Carl Zeiss Meditec $26.83  0.88% 
 Cooper Companies, Inc. $128.00  0.00% 
 Eleven Biotherapeutics $0.26  0.00% 
 Escalon Medical Corp. $0.95  0.00% 
 Essilor International $123.45  0.00% 
 Glaukos $14.91  0.00% 
 Imprimis Pharmaceuticals, Inc. $4.66  0.00% 
 Inotek Pharmaceuticals $6.38  0.00% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $8.98  0.00% 
 Johnson & Johnson $101.97  0.00% 
 Luxottica Group, S.p.A. $55.59  0.00% 
 Merck & Company, Inc. $49.16  0.00% 
 NicOx $6.96  2.23% 
 NovaBay Pharmaceuticals, Inc. $2.03  0.00% 
 Novartis AG Common Stock $72.62  0.00% 
 Ocular Therapeutix $5.54  0.00% 
 Ophthotech Corporation $46.34  0.00% 
 QLT $2.35  0.00% 
 Quantel $2.79  1.82% 
 Regeneron $365.97  0.00% 
 Roche $31.14  0.00% 
 Second Sight Medical Products $4.06  0.00% 
 Shire $151.22  0.00% 
 STAAR Surgical Company $6.19  0.00% 
 TearLab Corporation $0.65  0.00% 
 Thrombogenics $3.13  0.00% 
 Topcon Corporation $10.98  0.00% 
 Valeant Pharmaceuticals $86.95  0.00% 
 Xoma $0.77  0.00%